Tandem Diabetes Care, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tandem Diabetes Care, Inc.
FDA Clears Abbott’s Modified CGM For Automated Insulin Delivery Integration, Label Expansion
Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
JPM 2023: Boston Scientific Sees Transformational Potential In PFA, BD Sticks To '2025' Investment Strategy
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies; Some use the conference as a platform for major announcements while some just take the opportunity to explain their 2023 outlook to investors. Here are some of the highlights from the presentations on the third day of the meeting.
Don’t Develop It. Buy It! Tandem Buys AMF To Save Years Of R&D
To accelerate the development of its own patch-based insulin pump, Tandem Diabetes has purchased AMF Medical.
- Drug Delivery
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
In Vitro Diagnostics
- Glucose Testing
- Other Names / Subsidiaries
- AMF Medical
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.